{ "access": { "embargo": { "active": false, "reason": null }, "files": "public", "record": "public", "status": "open" }, "created": "2021-08-05T11:02:18.429946+00:00", "custom_fields": { "journal:journal": { "title": "Journal for ImmunoTherapy of Cancer" } }, "deletion_status": { "is_deleted": false, "status": "P" }, "files": { "count": 1, "enabled": true, "entries": { "e002694.full.pdf": { "checksum": "md5:62e84224bed76aea7971696d2b1932a2", "ext": "pdf", "id": "aaeedc93-728c-41f7-92fe-7a717342f317", "key": "e002694.full.pdf", "metadata": null, "mimetype": "application/pdf", "size": 1659518 } }, "order": [], "total_bytes": 1659518 }, "id": "5163297", "is_draft": false, "is_published": true, "links": { "access": "https://zenodo.org/api/records/5163297/access", "access_links": "https://zenodo.org/api/records/5163297/access/links", "access_request": "https://zenodo.org/api/records/5163297/access/request", "access_users": "https://zenodo.org/api/records/5163297/access/users", "archive": "https://zenodo.org/api/records/5163297/files-archive", "archive_media": "https://zenodo.org/api/records/5163297/media-files-archive", "communities": "https://zenodo.org/api/records/5163297/communities", "communities-suggestions": "https://zenodo.org/api/records/5163297/communities-suggestions", "doi": "https://doi.org/10.1136/jitc-2021-002694", "draft": "https://zenodo.org/api/records/5163297/draft", "files": "https://zenodo.org/api/records/5163297/files", "latest": "https://zenodo.org/api/records/5163297/versions/latest", "latest_html": "https://zenodo.org/records/5163297/latest", "media_files": "https://zenodo.org/api/records/5163297/media-files", "parent": "https://zenodo.org/api/records/5163296", "parent_doi": "https://zenodo.org/doi/", "parent_html": "https://zenodo.org/records/5163296", "requests": "https://zenodo.org/api/records/5163297/requests", "reserve_doi": "https://zenodo.org/api/records/5163297/draft/pids/doi", "self": "https://zenodo.org/api/records/5163297", "self_doi": "https://zenodo.org/doi/10.1136/jitc-2021-002694", "self_html": "https://zenodo.org/records/5163297", "self_iiif_manifest": "https://zenodo.org/api/iiif/record:5163297/manifest", "self_iiif_sequence": "https://zenodo.org/api/iiif/record:5163297/sequence/default", "versions": "https://zenodo.org/api/records/5163297/versions" }, "media_files": { "count": 0, "enabled": false, "entries": {}, "order": [], "total_bytes": 0 }, "metadata": { "creators": [ { "affiliations": [ { "name": "Experimental Oncology - Innovative Immunological Models, Istituto Nazionale per lo Studio e la Cura dei Tumori, \"Fondazione Pascale\"- IRCCS, Naples, Italy" } ], "person_or_org": { "family_name": "Ragone", "given_name": "C.", "name": "Ragone, C.", "type": "personal" } }, { "affiliations": [ { "name": "Experimental Oncology - Innovative Immunological Models, Istituto Nazionale per lo Studio e la Cura dei Tumori, \"Fondazione Pascale\"- IRCCS, Naples, Italy" } ], "person_or_org": { "family_name": "Manolio", "given_name": "C.", "name": "Manolio, C.", "type": "personal" } }, { "affiliations": [ { "name": "Experimental Oncology - Innovative Immunological Models, Istituto Nazionale per lo Studio e la Cura dei Tumori, \"Fondazione Pascale\"- IRCCS, Naples, Italy" } ], "person_or_org": { "family_name": "Cavalluzzo", "given_name": "B.", "name": "Cavalluzzo, B.", "type": "personal" } }, { "affiliations": [ { "name": "Experimental Oncology - Innovative Immunological Models, Istituto Nazionale per lo Studio e la Cura dei Tumori, \"Fondazione Pascale\"- IRCCS, Naples, Italy" } ], "person_or_org": { "family_name": "Mauriello", "given_name": "A.", "name": "Mauriello, A.", "type": "personal" } }, { "affiliations": [ { "name": "Esperimental Oncology - Molecular Biology and Viral Oncogenesis, Istituto Nazionale per lo Studio e la Cura dei Tumori, \"Fondazione Pascale\"- IRCCS, Naples, Italy" } ], "person_or_org": { "family_name": "Tornesello", "given_name": "M. L.", "name": "Tornesello, M. L.", "type": "personal" } }, { "affiliations": [ { "name": "Esperimental Oncology - Molecular Biology and Viral Oncogenesis, Istituto Nazionale per lo Studio e la Cura dei Tumori, \"Fondazione Pascale\"- IRCCS, Naples, Italy" } ], "person_or_org": { "family_name": "Buonaguro", "given_name": "F.", "name": "Buonaguro, F.", "type": "personal" } }, { "affiliations": [ { "name": "Institute for Applied Computing, CNR, Roma, Italy" } ], "person_or_org": { "family_name": "Castiglione", "given_name": "F.", "name": "Castiglione, F.", "type": "personal" } }, { "affiliations": [ { "name": "Institute for Biostructures and Bioimages, CNR, Roma, Italy" } ], "person_or_org": { "family_name": "Vitagliano", "given_name": "L.", "name": "Vitagliano, L.", "type": "personal" } }, { "affiliations": [ { "name": "Institute for Biostructures and Bioimages, CNR, Roma, Italy" } ], "person_or_org": { "family_name": "Laccarino", "given_name": "E.", "name": "Laccarino, E.", "type": "personal" } }, { "affiliations": [ { "name": "Institute for Biostructures and Bioimages, CNR, Roma, Italy" } ], "person_or_org": { "family_name": "Ruvo", "given_name": "M.", "name": "Ruvo, M.", "type": "personal" } }, { "affiliations": [ { "name": "Experimental Oncology - Innovative Immunological Models, Istituto Nazionale per lo Studio e la Cura dei Tumori, \"Fondazione Pascale\"- IRCCS, Naples, Italy" } ], "person_or_org": { "family_name": "Tagliamonte", "given_name": "M.", "name": "Tagliamonte, M.", "type": "personal" } }, { "affiliations": [ { "name": "Experimental Oncology - Innovative Immunological Models, Istituto Nazionale per lo Studio e la Cura dei Tumori, \"Fondazione Pascale\"- IRCCS, Naples, Italy" } ], "person_or_org": { "family_name": "Buonaguro", "given_name": "L.", "name": "Buonaguro, L.", "type": "personal" } } ], "description": "
Background The host’s immune system develops in equilibrium with both cellular self-antigens and non-selfantigens derived from microorganisms which enter the body during lifetime. In addition, during the years, a tumor may arise presenting to the immune system an additional pool of non-self-antigens, namely tumor antigens (tumorassociated antigens, TAAs; tumor-specific antigens, TSAs). Methods In the present study, we looked for homology between published TAAs and non-self-viralderived epitopes. Bioinformatics analyses and ex vivo immunological validations have been performed. Results Surprisingly, several of such homologies have been found. Moreover, structural similarities between paired TAAs and viral peptides as well as comparable patterns of contact with HLA and T cell receptor (TCR) α and β chains have been observed. Therefore, the two classes of non-self-antigens (viral antigens and tumor antigens) may converge, eliciting cross-reacting CD8+ T cell responses which possibly drive the fate of cancer development and progression. Conclusions An established antiviral T cell memory may turn out to be an anticancer T cell memory, able to control the growth of a cancer developed during the lifetime if the expressed TAA is similar to the viral epitope. This may ultimately represent a relevant selective advantage for patients with cancer and may lead to a novel preventive anticancer vaccine strategy.
", "funding": [ { "award": { "acronym": "iPC", "id": "00k4n6c32::826121", "identifiers": [ { "identifier": "https://cordis.europa.eu/projects/826121", "scheme": "url" } ], "number": "826121", "program": "H2020", "title": { "en": "individualizedPaediatricCure: Cloud-based virtual-patient models for precision paediatric oncology" } }, "funder": { "id": "00k4n6c32", "name": "European Commission" } } ], "languages": [ { "id": "eng", "title": { "en": "English" } } ], "publication_date": "2021-06-02", "publisher": "Zenodo", "resource_type": { "id": "publication-article", "title": { "de": "Zeitschriftenartikel", "en": "Journal article" } }, "rights": [ { "description": { "en": "The Creative Commons Attribution license allows re-distribution and re-use of a licensed work on the condition that the creator is appropriately credited." }, "icon": "cc-by-icon", "id": "cc-by-4.0", "props": { "scheme": "spdx", "url": "https://creativecommons.org/licenses/by/4.0/legalcode" }, "title": { "en": "Creative Commons Attribution 4.0 International" } } ], "title": "Identification and validation of viral antigens sharing sequence and structural homology with tumor- associated antigens (TAAs)" }, "parent": { "access": { "owned_by": { "user": 65392 } }, "communities": { "default": "22cf7730-a815-4310-9723-b18f7e6e5edb", "entries": [ { "access": { "member_policy": "open", "members_visibility": "public", "record_policy": "open", "review_policy": "open", "visibility": "public" }, "children": { "allow": false }, "created": "2019-04-18T15:21:01.347032+00:00", "custom_fields": {}, "deletion_status": { "is_deleted": false, "status": "P" }, "id": "22cf7730-a815-4310-9723-b18f7e6e5edb", "links": {}, "metadata": { "curation_policy": "Only publications related to the H2020 iPC Project will be curated.
\r\n", "page": "iPC will focus on identifying effective personalized medicine for paediatric cancers and will address a multitude of challenges. To meet these challenges, a comprehensive computational effort to combine knowledge base, machine-learning, and mechanistic models to predict optimal standard and experimental therapies for each child will be proposed. iPC will produce, assemble, standardize, and harmonize accessible high-quality multi-disciplinary data and leverage the potential of Big Data and HPC for the personalized treatments of European citizens.
\r\n\r\nThe goal of the iPC project is to collect, standardize and harmonize existing clinical knowledge and medical data and, with the help of artificial intelligence, create treatment models for patients. Armed with these treatment models, scientists will then test them on virtual patients to evaluate treatment efficacy and toxicity, thus improving both patient survival and their quality of life.
\r\n\r\nTo accomplish those goals, an interdisciplinary team consisting of basic, translational, and clinical researchers — all amongst the leaders in their respective fields — was assembled and established strong relationships with European Centres of Excellence, patient organizations, and clinical trials focus on personalized medicine for the proposed case studies.
\r\n\r\nIn summary, iPC will address the critical need for personalized medicine for children with cancer, contribute to the digitalization of clinical workflows, and enable the Digital Single Market of the EU data infrastructure.
", "title": "iPC" }, "revision_id": 0, "slug": "ipc", "updated": "2019-04-18T15:21:34.123501+00:00" }, { "access": { "member_policy": "open", "members_visibility": "restricted", "record_policy": "open", "review_policy": "closed", "visibility": "public" }, "children": { "allow": true }, "created": "2022-11-23T15:53:29.436323+00:00", "custom_fields": {}, "deletion_status": { "is_deleted": false, "status": "P" }, "id": "f0a8b890-f97a-4eb2-9eac-8b8a712d3a6c", "links": {}, "metadata": { "curation_policy": "The EU Open Research Repository serves as a repository for research outputs (data, software, posters, presentations, publications, etc) which have been funded under an EU research funding programme such as Horizon Europe, Euratom or earlier Framework Programmes.
\nThe community is managed by CERN on behalf of the European Commission.
\nZenodo’s general policies and Terms of Use apply to all content.
\nThe EU Open Research Repository accepts all digital research objects which is a research output stemming from one of EU’s research and innovation funding programmes. The funding programmes currently include:
\nHorizon Europe (including ERC, MSCA), earlier Framework Programmes (eg Horizon 2020) as well as Euratom.
\nIn line with the principle as open as possible, as closed as necessary both public and restricted content is accepted. See note on how Zenodo handles restricted content.
\nEU programme beneficiaries are eligible to submit content to the community. The community supports three types of content submissions:
\nSubmission via an EU Project Community (through user interface or programmatic APIs).
\nSubmission directly to the EU Open Research Repository.
\nAutomated harvesting from existing Zenodo content.
\nA representative of an EU project may request an EU Project Community and invite other project participants as members of the community. The project community is linked to one or more European Commission grants. All records in the project community are automatically integrated into the EU Open Research Repository immediately upon acceptance into the project community.
\nAny user may submit a record directly to the EU Open Research Repository. The submission will be moderated by Zenodo staff for compliance with the minimal required metadata requirements and its correctness.
\nRecords found among Zenodo’s existing content will on a regular basis automatically be integrated if they are found to comply with the requirements. The submissions through this method are integrated into the EU Open Research Repository with delay in a fully automated way.
\nRecords in the EU Open Research Repository are required to comply with the following minimal metadata requirements:
\nVisibility: Both public and restricted (with or without embargo and/or access request)
\nResource types: All resource types.
\nLicenses: Public and embargoed records MUST specify a license.
\nFunding information: Records MUST specify at least one grant from the European Commission.
\nCreators: Creators SHOULD be identified with a persistent identifier (e.g. ORCID, GND, …), and affiliations SHOULD be identified with a persistent identifier (e.g. ROR, ISNI, …)
\nSubjects: Records SHOULD specify one or more fields of science from the European Science Vocabulary.
\nAll submissions will undergo automated curation checks for compliance with the policy. Submissions through project communities are reviewed by the project community. Submission directly to the EU Open Research Repository is reviewed by Zenodo staff.
\nCommunity curators may at any point edit metadata of the records in the community without notice through human or automated processing. The curators may at their sole discretion remove records from the community that are deemed not to comply with the content and curation policy or which are deemed of insufficient quality.
\nThe content and curation policy is subject to change by the community owner at any time and without notice, other than through updating this page.
", "description": "Open repository for EU-funded research outputs from Horizon Europe, Euratom and earlier Framework Programmes.", "organizations": [ { "id": "00k4n6c32" } ], "page": "The EU Open Research Repository is a Zenodo-community dedicated to fostering open science and enhancing the visibility and accessibility of research outputs funded by the European Union. The community is managed by CERN on behalf of the European Commission.
\nThe mission of the repository is to support the implementation of the EU's open science policy, providing a trusted and comprehensive space for researchers to share their research outputs such as data, software, reports, presentations, posters and more. The EU Open Research Repository simplifies the process of complying with open science requirements, ensuring that research outputs from Horizon Europe, Euratom, and earlier Framework Programmes are freely accessible, thereby accelerating scientific discovery and innovation.
\nThe EU Open Research Repository serves as a complementary platform to the Open Research Europe (ORE) publishing platform. Open Research Europe focuses on providing a publishing venue for peer-reviewed articles, ensuring that research meets rigorous academic standards. The EU Open Research Repository provides a space for all the other research outputs including data sets, software, posters, and presentations that are out of scope for ORE. This holistic approach enables researchers to not only publish their findings but also share the underlying data and materials that support their work, fostering transparency and reproducibility in the scientific process.
\nCurrently in its pilot phase and set to be fully operational during autumn 2024, the EU Open Research Repository is constantly evolving. Efforts are committed to integrating cutting-edge features, including automated curation checks and FAIR (Findable, Accessible, Interoperable, and Reusable) assistance, to further support the research community. The goal is to provide researchers with a simple goto solution for making their publicly funded research open and as FAIR as possible.
\nThe EU Open Research Repository is funded by the European Union under grant agreement no. 101122956(HORIZON-ZEN). For more information about the project see https://about.zenodo.org/projects/horizon-zen/.
", "title": "EU Open Research Repository (Pilot)", "type": { "id": "organization" }, "website": "https://research-and-innovation.ec.europa.eu" }, "revision_id": 16, "slug": "eu", "theme": { "brand": "horizon", "enabled": true, "style": { "font": { "family": "Arial, sans-serif", "size": "16px", "weight": 600 }, "mainHeaderBackgroundColor": "#FFFFFF", "primaryColor": "#004494", "primaryTextColor": "#FFFFFF", "secondaryColor": "#FFD617", "secondaryTextColor": "#000000", "tertiaryColor": "#e3eefd", "tertiaryTextColor": "#1c5694" } }, "updated": "2024-03-20T06:47:47.577483+00:00" } ], "ids": [ "22cf7730-a815-4310-9723-b18f7e6e5edb", "f0a8b890-f97a-4eb2-9eac-8b8a712d3a6c" ] }, "id": "5163296", "pids": {} }, "pids": { "doi": { "identifier": "10.1136/jitc-2021-002694", "provider": "external" }, "oai": { "identifier": "oai:zenodo.org:5163297", "provider": "oai" } }, "revision_id": 2, "stats": { "all_versions": { "data_volume": 139399512.0, "downloads": 84, "unique_downloads": 84, "unique_views": 186, "views": 202 }, "this_version": { "data_volume": 136080476.0, "downloads": 82, "unique_downloads": 82, "unique_views": 176, "views": 190 } }, "status": "published", "updated": "2021-08-05T13:48:27.340678+00:00", "versions": { "index": 1, "is_latest": true } }